STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending

Article excerpt

The American Diabetes Association's annual conference is underway, featuring updates on diabetes treatment approaches both novel and established. Day two brings news about triple hormone receptor therapies and a monthly obesity medication, alongside what the outlet characterizes as a bittersweet development in the field. The full details remain behind STAT's subscription paywall.